Your shopping cart is currently empty

K-252a is a protein kinase inhibitor targeting serine-threonine, tyrosine, and CAM kinases. In vitro, it blocks NGF-induced TrkA signalling and neural differentiation, exhibiting antitumour, antibacterial, anti-inflammatory, and neuroprotective activities.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $99 | - | In Stock |
| Description | K-252a is a protein kinase inhibitor targeting serine-threonine, tyrosine, and CAM kinases. In vitro, it blocks NGF-induced TrkA signalling and neural differentiation, exhibiting antitumour, antibacterial, anti-inflammatory, and neuroprotective activities. |
| Targets&IC50 | Ca2+/calmodulin-dependent kinase type II:270 nM, Phosphorylase kinase:1.7 nM, PKA:140 nM, PKC:470 nM |
| In vitro | Methods: LINC00641 overexpressing cell lines were treated with K-252a (1.7 nM, 6 hours), and the expression of target proteins in cells was detected by Western blotting. Results: K-252a can reduce the levels of p-Akt and p-TrkB in LINC00641 overexpressing cell lines. [3] Methods: PC12 subclone h cells were treated with K-252a (3-100 nM, 8 days) to study its effect on cell viability. Results: K-252a can inhibit NGF-induced neurite outgrowth. [4] |
| In vivo | Methods: Mice were treated with K-252a (20 mg/kg, intraperitoneal injection, once a day for 5 days) and their neurological function was evaluated. Results: K-252a was able to inhibit the TH-induced neuroprotective effect in mice. [5] |
| Synonyms | SF2370, Antibiotic SF 2370, Antibiotic K 252a |
| Molecular Weight | 467.47 |
| Formula | C27H21N3O5 |
| Cas No. | 99533-80-9 |
| Smiles | C[C@]12N3C=4C5=C(C6=C(C4C=7C3=CC=CC7)CNC6=O)C=8C(N5[C@](O1)(C[C@@]2(C(OC)=O)O)[H])=CC=CC8 |
| Relative Density. | 1.67g/cm3 |
| Storage | store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (85.57 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.